Evidence map›Paper›PMID 39820580›Full record

Trial reportDiabetologia2025

Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.

Ildiko Lingvay, Malik Benamar, Liming Chen, Ariel Fu, Esteban Jódar, Tomoyuki Nishida, Jean-Pierre Riveline, Daisuke Yabe, Thomas Zueger, Rosângela Réa

Erratum issued Registry-linked trialAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It reports registered trial NCT05259033. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05259033 phase3completed

A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Semaglutide, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With a GLP 1 Receptor Agonist. COMBINE 2

Ran2022Enrolled683Registered outcomes6Posted comparisons1ConditionsDiabetes Mellitus, Type 2ArmsIcoSema, Semaglutide 1 mg
Open the trial in the graph
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Ildiko LingvayEndocrinology Division, Department of Internal Medicine and Peter O'Donnell Jr School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA. Ildiko.Lingvay@UTSouthwestern.edu.ORCID http://orcid.org/0000-0001-7006-7401
Malik BenamarNovo Nordisk A/S, Søborg, Denmark.ORCID http://orcid.org/0009-0001-1820-1527
Liming ChenNHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.ORCID http://orcid.org/0000-0002-5682-2340
Ariel FuNovo Nordisk A/S, Søborg, Denmark.ORCID http://orcid.org/0009-0007-0220-5877
Esteban JódarUniversitary Hospital QuironSalud Madrid, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.ORCID http://orcid.org/0000-0002-1234-8560
Tomoyuki NishidaNovo Nordisk Pharma Ltd, Tokyo, Japan.ORCID http://orcid.org/0009-0004-5812-7167
Jean-Pierre RivelineDepartment of Endocrinology and Diabetology, Lariboisière Hospital, APHP, Paris-Cité University Paris, Paris, France.ORCID http://orcid.org/0000-0001-7991-0741
Daisuke YabeDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID http://orcid.org/0000-0002-5334-7687
Thomas ZuegerDepartment of Endocrinology, Diabetes and Metabolic Diseases, Kantonsspital Olten, Olten, Switzerland.ORCID http://orcid.org/0000-0001-6190-7405
Rosângela RéaInternal Medicine Department, Endocrine Division (SEMPR), Universidade Federal do Paraná, Curitiba, Brazil.ORCID http://orcid.org/0000-0002-2102-0495

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisCOMBINE 2 assessed the efficacy and safety of once-weekly IcoSema (a combination therapy of basal insulin icodec and semaglutide) vs once-weekly semaglutide (a glucagon-like peptide-1 analogue) 1.0 mg in individuals with type 2 diabetes inadequately managed with GLP-1 receptor agonist (GLP-1 RA) therapy, with or without additional oral glucose-lowering medications.

methodsThis 52 week, randomised, multicentre, open-label, parallel group, Phase IIIa trial was conducted across 121 sites in 13 countries/regions. Adults with type 2 diabetes (HbA

resultsOverall, 683 participants were randomised using a Randomisation and Trial Supply Management system to IcoSema (n=342) or semaglutide 1.0 mg (n=341). Mean ± SD baseline characteristics were as follows: HbA CONCLUSIONS/

interpretationIn people living with type 2 diabetes inadequately managed with GLP-1 RA therapy, with or without additional oral glucose-lowering medications, switching to once-weekly IcoSema in comparison with once-weekly semaglutide 1.0 mg demonstrated superiority in HbA

trial registrationClinicalTrials.gov NCT05259033

fundingThis trial was funded by Novo Nordisk.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsAdultAgedBlood GlucoseDrug Administration ScheduleDrug Therapy, CombinationFemaleGlucagon-Like Peptide 1Glycated HemoglobinHumansInsulin GlargineMaleMiddle AgedSemaglutideBlood GlucoseGlucagon-Like Peptide 1Glucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsInsulin GlargineSemaglutideFixed-ratio combinationGLP-1 RAGlycaemic controlHypoglycaemiaIcoSemaInsulin icodecOnce-weeklySafetySemaglutideType 2 diabetes

Identifiers

PMID39820580
PMCPMC11950020

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.